08:57 AM EDT, 08/20/2025 (MT Newswires) -- Phathom Pharmaceuticals ( PHAT ) said Wednesday that a Schedule 13D filing by shareholder Frazier Life Sciences will include administrative changes to its reporting approach but does not mean a reduction in the ownership of any Frazier fund or person in Phathom.

The company said the breakout of holdings might appear different and treatment of warrants may lower certain percentages, but these are merely due to changes in Frazier's reporting approach and not to any sale of shares.

The 13D filing is expected later in the day, Phathom added.